UPDATE: MannKind (MNKD) Says Advancing Inhaled EpiPen Rival, May Seek Partner

September 2, 2016 3:24 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - September 2, 2016 3:31 PM EDT)

MannKind (Nasdaq: MNKD) advancing inhaled EpiPen rival and may seek a partner, according to Bloomberg, citing the company's CEO, Matt Pfeffer.

UPDATE - Pfeffer said the company isn't looking to raise capital now, but may evaluate its needs as the epinephrine pen moves into human testing. A capital raise would depend on Afrezza sales.

Epinephrine is lead drug in MannKind's pipeline and hasn't slowed down even as the company has moved to conserve cash.

MannKind's cash and cash equivalents were $63.7 million at the end of CQ15.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment